Renal Cell Carcinoma News
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.
Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.
CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.
Renal cell carcinoma trials conducted in the past 10 years used exclusion criteria deemed potentially excessive by ASCO and FCR.
Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.
Second progression-free survival is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.
Adding ilixadencel to treatment with sunitinib does not appear to improve outcomes in patients with metastatic renal cell carcinoma undergoing nephrectomy.
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Immunotherapy-based combinations have overtaken TKI monotherapy as the most-used first-line treatment for mRCC in US oncology clinics, a study suggests.
Tivozanib improves long-term progression-free survival, when compared with sorafenib, in patients with relapsed or refractory metastatic renal cell carcinoma, an analysis suggests.
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
The risk for end-stage renal disease is 10 times higher in patients with renal cell carcinoma than in the general population, a study suggests.
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Real-world data suggest similar overall survival outcomes with frontline ipilimumab-nivolumab or axitinib-pembrolizumab in patients with metastatic renal cell carcinoma.
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.
Vegzelma is a vascular endothelial growth factor inhibitor.
The study included a large, contemporary cohort of patients with T1a renal cell carcinoma undergoing partial nephrectomy or local tumor destruction.
A real-world study revealed an objective response rate consistent with that observed in the CheckMate 214 trial.
Adjuvant pembrolizumab could be a new standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, according to researchers.